Learn how CBD Certification from LegitScript helps manufacturers and merchants of legally compliant CBD products show the highest level of credibility. cbdMD, Inc. (NYSE American: YCBD, YCBDpA), one of the world’s leading and most highly trusted and recognized health & wellness CBD companies, toda The online Professional Certificate of Medicinal Cannabis provides an introduction to the therapeutic uses of cannabis to treat patients in Australia.
When it comes to CBD, customers (rightfully) have questions. Demonstrate your commitment to compliance with LegitScript CBD certification.
Your Customers Want CBD They Can Trust
CBD regulations are always changing. But what customers want remains the same: quality, transparency, and safety.
When your CBD website is LegitScript-certified, customers can rest assured your CBD products check all the boxes: Third-party tested. FDA-compliant. Free of impermissible levels of THC.
Commit to Transparency
CBD Website Certification: Because You’re Not Like the Others
In a market with ever-evolving regulations, it’s all too common for bad actors to flood the scene with substandard or tainted products. And when there are few certification standards, it can be that much harder for legitimate merchants to stand out from the crowd.
That’s why leading CBD manufacturers and merchants are turning to LegitScript. Get certified. Gain trust. It’s a win-win all around.
Stay Up To Date with the Latest CBD Information
Take a Stand for Your Customers
The Latest News for CBD Manufacturers and Merchants
On recent news that the White House is exploring the possibility of creating a federal task force to “explore the potential of psychedelic-assisted therapies” in the United States, certain psychoactive substances seem to be having a moment. Public awareness of these substances appears to be increasing in tandem with government interest; take, for example, the…
on August 08, 2022
While Many Focus on the Problem of Disinformation, This Other Form of Information Poses Dangers to Users Online
While misinformation and disinformation on social media frequently capture news headlines, other forms of information can pose reputational risks to internet platforms and potential harm to consumers or others around them. LegitScript has encountered users and merchants on social media platforms posting various types of instructions that may be framed as being for informational use…
on July 14, 2022
In this episode of Merchant Risk Live, we spoke with CJ Schneller, Senior Vice President of Risk and Compliance at MerchantE, on building strong risk and compliance habits into the fabric of an organization. Watch the full episode by clicking the button below, or continue reading to get highlights. Watch Now Prior to joining MerchantE,…
on June 15, 2022
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
|cookielawinfo-checkbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category “Analytics”.|
|cookielawinfo-checkbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category “Functional”.|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category “Necessary”.|
|cookielawinfo-checkbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category “Other.|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category “Performance”.|
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
cbdMD Becomes the First CBD Company to Earn Prestigious NSF International’s Certified for Sport ® Certification
CHARLOTTE, N.C.–( BUSINESS WIRE )–cbdMD, Inc. (NYSE American: YCBD, YCBDpA), one of the world’s leading and most highly trusted and recognized health & wellness CBD companies, today announced that it is the first and only CBD company to earn the highly respected designation of NSF Certified for Sport, ® which opens the door to acceptance by major sports leagues in the USA and internationally.
The Company’s award-winning, patent-pending proprietary broad spectrum hemp extract blend containing CBD, CBG and CBN passed the rigorous testing standards set forth by NSF International. Four of the Company’s flagship products containing this blend were specifically submitted for Certified for Sport ® certification. The Company’s 30-count 1500 mg CBD oil softgels, 60-count 3000 mg CBD oil softgels, 30-count 500 mg PM softgels, and 60-count 1000 mg PM softgels each earned certification from NSF International’s Certified for Sport ® program. The Company intends to submit additional products in the near future, and is confident that the rest of its dietary supplement portfolio will achieve approval.
NSF International is a global public health organization that tests and certifies products to help protect athletes and consumers from potentially harmful ingredients and athletic banned substances in dietary supplements. Products earning Certified for Sport ® certification are tested for over 280 athletic banned substances as well as potentially harmful levels of specific contaminants like lead and arsenic. Product formulation, label claims and Good Manufacturing Practice (GMP) compliance are also verified as part of this rigorous supplement certification program.
NSF International’s Certified for Sport ® program helps athletes and consumers make more knowledgeable decisions when choosing supplements. MLB, NHL and CFL clubs provide and recommend products that are Certified for Sport ® and players are urged to use only these certified products. The Certified for Sport ® certification is also recommended by the NFL, PGA, LPGA, CCES, CPSDA and Taylor Hooton Foundation as well as many other sports organizations. This certification comes on the heels of the NFL’s recent announcement that they awarded $1 million in research funding to two teams of medical researchers at the University of California San Diego and University of Regina. The studies will investigate the effects of cannabinoids on pain management and neuroprotection in elite football players, respectively.
“NSF International welcomes cbdMD to the Certified for Sport ® program as the first and only CBD company to do so to date. NSF International is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport ® requirements, cbdMD is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes,” said David Trosin, Managing Director, Health Sciences Certification at NSF International.
“We are beyond proud to be the first CBD company to achieve this designation. cbdMD has always maintained a focus on crafting high-quality products that are designed specifically with the safety of our consumers in mind. This prestigious honor further solidifies our stand as a leader and innovator within the industry, constantly striving to create real regulation and industry standards. We’re thrilled to offer these exclusive products to our customers, and we’re excited to see what doors this opens in the future,” said co-CEO of cbdMD, Inc. Martin Sumicharst.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands with a comprehensive line of U.S.-produced, THC-free 1 CBD products. The cbdMD brand currently includes over 130 SKUs of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids, CBD drink mixes and full spectrum CBD options. Our Paw CBD brand of pet products includes over 45 SKUs of veterinarian-formulated products including tinctures, chews and topical products in varying strengths, and our cbdMD Botanicals brand of beauty and skincare products features 15 SKUs, including facial oil and serum, toner, moisturizers, facial masks, exfoliants and body care. To learn more about cbdMD and their comprehensive line of U.S.-grown, THC-free 1 CBD oil and full spectrum products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the 6,000 retail outlets that carry cbdMD products.
About NSF International
NSF International (nsf.org) is a global public health organization that facilitates standard development, and tests and certifies products for the health sciences, food, water and consumer goods industries to minimize adverse health effects and protect the environment. Founded in 1944, NSF is committed to protecting human health and safety worldwide. Operating in more than 175 countries, NSF International is a Pan American Health Organization/World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to the expansion of the consumer market for CBD products, our ability to increase our market share, the availability of the Amazon platform for our CBD products, our ability to expand our business and significantly increase our revenues, our ability to effectively leverage our brand partnerships and sponsorships, our ability to effectively compete in our market, our ability to achieve our net sales guidance, and our ability to report profitable operations in the future. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1 THC-free is defined as below the level of detection using validated scientific methods.
Director of Public Relations
Director of Investor Relations
Professional Certificate of Medicinal Cannabis (Online)
The Professional Certificate of Medicinal Cannabis equips medical practitioners with the knowledge to safely apply cannabis as a medicinal tool for patients with common ailments in primary care.
You will learn about the endocannabinoid system and the properties of THC and CBD; explore the routes of administration, side effects and contraindications of medicinal cannabis; and draw upon real patient cases and common conditions seen in general practice, including chronic pain, anxiety, insomnia, depression, and cancer.
The evidence-backed, science-based online program teaches how and why medicinal cannabis works, enabling you to provide holistic care and optimal outcomes for your patients.
GPs working in Australia (except for in Tasmania) may prescribe Medicinal Cannabis, however, as part of the guidelines of the TGA SAS-B, you will need to indicate that you have the knowledge necessary to do so. This program will equip you with the knowledge required to manage and prescribe Medicinal Cannabis for various conditions and can serve as part of your documentation showing that you have undertaken education in this field when you decide to become an authorised prescriber. More information here.
This course is the first stage of the three-part Professional Diploma of Medical Cannabis. The education pathway is Professional Certificate of Medicinal Cannabis, Advanced Certificate of Medicinal Cannabis and Professional Diploma of Medicinal Cannabis.
ENTRY REQUIREMENTS AND COURSE REQUISITES
This Professional Certificate of Medicinal Cannabis is for medical doctors who wish to learn how to improve patient outcomes with medicinal cannabis, especially those patients with conditions commonly seen in general practice. This qualification is the first stage of the Professional Diploma of Medicinal Cannabis.
This course is for physicians and degree-qualified medical professionals. There are no prerequisites. Participants do not have to pass an IELTS test but, as the courses are delivered in English, proficiency in listening, reading and writing English is assumed.
Participants will require access to a computer/laptop, an internet connection and a basic level of technology proficiency to access and navigate the online learning portal.
Professionally recognised qualifications and prior studies may be recognised for entry into this course if the learning outcomes match exactly. Please ask a HealthCert Education Advisor for an individual assessment of your prior qualifications and experience.
- Introduction to the endocannabinoid system
- Exploring THC and CBD
- Routes of administration, side effects and contraindications
- Patient cases and basic ailments
- History of cannabis and medical acceptance
- Chronic pain and medical cannabis
- Anxiety, insomnia and depression
- Cancer symptomatic treatment
Course participants will:
- Have the opportunity to replay video lectures from medical experts.
- Participate in discussion of patient cases, evaluate and make decisions.
- Receive access to research/readings in the field.
- Participate in course webinars prior to the examinations and ask questions.
- Receive ongoing support post-course through webinars and case review.
- Receive unlimited and ongoing access to free alumni learning resources, video lectures, and discussion forums, as well as invite-only events and special offers after completion of the course.
Module 1: Introduction to the endocannabinoid system
Module 2: Exploring THC and CBD
Module 3: Routes of administration, side effects and contraindications
Module 4: Patient cases and basic ailments
Module 5: History of cannabis and medical acceptance
Module 6: Chronic pain and medical cannabis
Module 7: Anxiety, insomnia and depression
Module 8: Cancer symptomatic treatment
Module One: History of Cannabis and Medical Acceptance
This module considers the cannabis plant and its rich and colourful history as a psychotropic agent, a commodity, a sacred entity, and a medicine to treat a raft of disorders. Maligned and criminalised in the second half of the 20th century, cannabis is now in a new cycle with a burgeoning and sustained scientific interest in its potential medical uses. The module also outlines the history behind the discovery of different cannabis strains, specific phytocannabinoids (e.g., THC), endocannabinoids (e.g., AEA) and the body’s innate endocannabinoid system, and the myriad of biological processes to which it is linked. Finally, the module looks at the discovery of terpenes, and with it, the so-called entourage effect or the synergism between the multitude of compounds within the whole plant.
Module Five: Patient Cases and Basic Ailments
This module identifies a number of basic ailments that may be successfully treated with medical cannabis in General Practice. For example, the adverse effects of cancer treatment, the symptoms of chronic pain, anxiety, depression, and insomnia could be alleviated by medicinal cannabis with mild side effects and minimal risk of toxicity or addiction. Providing that conventional treatments have failed or caused unacceptable side effects, a growing number of conditions lend themselves to treatment with cannabis. Given the complex chemical profile, there is a single medication potential to assist with multiple symptoms, thereby reducing polypharmacy. The module applies an individualised management plan to three comprehensive case studies for patients with chronic pain, osteoarthritis, and anxiety and depression. Considerations ranging from the cost to the patient to the appropriate THC to CBD ratio are addressed. Finally, the module guides the practitioner in navigating an application for a TGA Special Access Scheme/SAS B.
Module Two: Introduction to the Endocannabinoid System
This module analyses the homeostatic endocannabinoid system and its broad scope of influence in both health and disease. The endocannabinoid system’s three central instruments are established, the endocannabinoids, receptors, and enzymes, followed by an analysis of the system’s homeostatic functions, including analgesia, mood, energy balance, and stress coping. Evidence for the relationship between insufficiency or dysregulation of the endocannabinoid system and particular disorders is also discussed. Finally, the module provides an overview of our current understanding of cannabinoids, such as THC and CBD, and how ongoing research into targeted manipulation of the endocannabinoid system with active cannabinergic compounds may prove therapeutic in numerous pathological conditions.
Module Six: Chronic Pain and Medicinal Cannabis
This module discusses the use of medicinal cannabis as an emerging option for clinicians to reduce and alleviate difficult-to-treat, chronic, neuropathic pain. The module analyses the endocannabinoid system and the diverse, multimodal mechanisms of cannabinoid-induced analgesia. THC and CBD are an excellent additive treatment to concurrent conventional pain management for many chronic pain types associated with a range of diseases such as fibromyalgia, traumatic injury, and multiple sclerosis. For patients suffering from neuropathic pain, cannabinoids may be used successfully as an adjunctive, opioid-sparing, or ultimately a replacement therapy for managing their pain. The module also discusses a management plan’s necessary considerations (such as determining dosages and accounting for safety considerations) and applies these protocols to a chronic pain case study.
Module Three: Exploring THC and CBD
This module provides a comprehensive examination of the two main cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD); it distinguishes between their main actions and analyses their synergistic relationship. Given that THC and CBD interact differently within the endocannabinoid system and with other neurotransmitters, the module considers their different therapeutic potential, bioavailability, metabolism, toxicology, and dosing. The module also describes the most up-to-date method of cannabis classification, or chemovars, a method based on chemical composition in order to match a specific profile to a particular treatment. For example, chemovars establish the CBD to THC ratio in a given ‘species’ as well as other cannabinoids involved in whole plant medicine, such as CBG, CBN, and CBC. They also determine the presence of other important constituents, such as a wide variety of terpenes.
Module Seven: Anxiety, Insomnia and Depression
This module examines the homeostatic functions of the endocannabinoid system in relation to mood, stress response, and sleep. It also evaluates the therapeutic capacity of the major cannabinoids (THC and CBD), in isolation and in synergy, in relation to anxiety, depression, and insomnia. In developing a treatment plan, essential factors such as the interplay between depression, anxiety, pain, and insomnia are considered, as well as protocols for THC to CBD ratios in basic dosing, and the route and timing of administration with reference to each condition. With regard to treating insomnia particularly, the module addresses the role of other lesser-known cannabinoids, such as CBN, and terpenes. Pertinent considerations such as the dampening effect of CBD upon the undesirable effects of THC such as intoxication, tachycardia and psycho-activity (of particular importance when treating anxiety) are also discussed.
Module Four: Routes of Administration, Side Effects and Contra Indications
This module discusses the safe use of medicinal cannabis, outlining the routes of administration, side effects, and contraindications. Cannabinoid pharmacokinetics are also examined, including its absorption following diverse administration routes, metabolism by different tissues and organs, bioavailability and elimination from the body. Despite its extreme safety as a medication generally and particularly relative to opioids, potential adverse effects and contrindicaitons of cannabis are outlined. The module also analyses the potential for drug-to-drug interaction given CBD and THC’s effects on common biological pathways implicated in drug metabolism via their interactions with cytochrome P450 enzymes specifically.
Module Eight: Cancer: Symptomatic Treatment
This module reviews the myriad of functions of cannabinoids and the endocannabinoid system and considers the supportive role they may have to play in cancer therapy. Although research continues into the anti-tumour properties of cannabinoids, there is currently no evidence that medical cannabis can cure or even treat cancer. Nonetheless, it can be a successful additional therapy used in the management of cancer symptoms and the iatrogenic effects of treatment. The judicious use of medicinal cannabis can significantly improve cancer sufferers’ quality of life by managing persistent symptoms and side effects such as, cancer pain, nausea, vomiting, and chemotherapy-induced nausea and vomiting. The module also considers the case studies of three different cancer patients and, for each, examines issues for the clinician related to assessment, dosing recommendations, formulation, methods of administration, and side effects.